Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Other financing activities (2022 - 2023)

Seres Therapeutics (MCRB) has disclosed Other financing activities for 2 consecutive years, with -$529000.0 as the latest value for Q3 2023.

  • Quarterly Other financing activities fell 116.13% to -$529000.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $3.3 million through Sep 2023, changed N/A year-over-year, with the annual reading at $425000.0 for FY2019, N/A changed from the prior year.
  • Other financing activities hit -$529000.0 in Q3 2023 for Seres Therapeutics, down from $304000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $3.3 million in Q3 2022 to a low of -$529000.0 in Q3 2023.